Head and Neck Squamous Cell Carcinoma | Nano Publications

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Preoperative radiotherapy (RT) is an option for a subset of patients with locally advanced primary or relapsed tumors. Yet, its impact on efficacy in terms of pathological response is limited, highlighting the need for novel multimodal therapies aimed at local control with low toxicity. NBTXR3 is made of hafnium oxide nanoparticles which, injected intratumorally (IT) and activated by ionizing radiation, yield a tumor-localized high energy deposit and increase cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Despite proven efficacy, a limited number of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or metastatic non-small cell lung cancer (NSCLC) benefit from anti-PD-1 treatment. Indeed, most pts do not respond to initial therapy due to intrinsic re-sistance to checkpoint inhibition. There is thus an important unmet medical need for a curative treatment in these pts and converting the local immune microenvironment to a “hot” phenotype may help to overcome therapeutic resistance. […]

Continuer la lecture…

2021 – Eur J Cancer – NBTXR3 Phase I in HNSCC

Donnée clinique de NBTXR3, NO-RIGHTS, Publications, Tête & Cou

This phase I study assessed the safety of first-in-class radioenhancer nanoparticles, NBTXR3, in elderly or frail patients with locally advanced head and neck squamous cell carcinoma (HNSCC), ineligible for chemoradiation. This is an observational, retrospective, international, study of adult patients with primary non-metastatic STS of the extremities and trunk wall, any grade, diagnosed between 2008 and 2012, treated with at least neoadjuvant treatment and surgical resection and observed for a minimum of 3 years after diagnosis. […]

Continuer la lecture…